Rare disease

Pancreatic carcinoma metastatic

35 clinical trials

Quick filters

Clinical trials for Pancreatic carcinoma metastatic

35 trials across Europe

See all trials →

Quick filters

35 Clinical trials

Pancreatic carcinoma metastatic

Recruiting

Registered drugNo placebo

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Gemcitabine
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Registered drug

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Incyte Corp.

Contact Research Centre

Pancreatic carcinoma metastatic+1

Recruiting

Registered drug

A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Gemcitabine
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Pancreatic carcinoma metastatic+1

Recruiting

InvestigationalNo placebo

Study of TCR-Modified T Cell Therapy with ANOC-001, ANOC-002, and ANOC-003 for Adults with Advanced Pancreatic Cancer

InvestigationalNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:ANOC-001
Sponsor:Anocca AB

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Registered drugNo placebo

Study on the Safety of Tumor Treating Fields with Oxaliplatin, Calcium Folinate, Irinotecan Hydrochloride, and Fluorouracil for Metastatic Pancreatic Cancer Patients

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Clinica Universidad De Navarra

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Registered drugNo placebo

Study of Ginisortamab with Nab-Paclitaxel and Gemcitabine or MEK Inhibitor for Patients with Metastatic Pancreatic Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cobimetinib
Sponsor:Cancer Research UK

Contact Research Centre

See all trials →

Pancreatic carcinoma metastatic

Clinical trials for Pancreatic carcinoma metastatic

Pancreatic carcinoma metastatic

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Pancreatic carcinoma metastatic

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Pancreatic carcinoma metastatic+1

A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

Pancreatic carcinoma metastatic+1

Study of TCR-Modified T Cell Therapy with ANOC-001, ANOC-002, and ANOC-003 for Adults with Advanced Pancreatic Cancer

Pancreatic carcinoma metastatic

Study on the Safety of Tumor Treating Fields with Oxaliplatin, Calcium Folinate, Irinotecan Hydrochloride, and Fluorouracil for Metastatic Pancreatic Cancer Patients

Pancreatic carcinoma metastatic

Study of Ginisortamab with Nab-Paclitaxel and Gemcitabine or MEK Inhibitor for Patients with Metastatic Pancreatic Cancer

Filter the trials

Prefer not to search? Our Concierge searches the trials for you.